Xadago (safinamide)
- Region
- 🇪🇺 EU
- Active substance
- safinamide
- Company
- Zambon SpA
- Status
- Authorised
- Therapeutic area
- Parkinson Disease
- EU approval
- Mon 23 Feb 2015
- Application
- EMEA/H/C/002396
- ATC
- N04B
- Official record
- www.ema.europa.eu
Indication
Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.
Regulatory milestones
No milestones recorded in the last year.
Follow Xadago
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.